GSE189772 GSE189773 CTB CTBp 0 v 1 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE189772_GSE189773_CTB_CTBp_0_v_1_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE189772_GSE189773_CTB_CTBp_0_v_1_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE189772_GSE189773_CTB_CTBp_0_v_1_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE189772_GSE189773_CTB_CTBp_0_v_1_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

mitochondrial ribosomal protein L45

Gene

long intergenic non-protein coding RNA 869

Gene

zinc finger domain-containing protein LOC728743

Gene

IGFL2 antisense RNA 1

Gene

MIR124-1 host gene

Gene

RNA component of signal recognition particle 7SL1

Gene

napsin B aspartic peptidase (pseudogene)

Gene

MPDU1 antisense RNA 1

Gene

Fc gamma receptor Ib, pseudogene

Gene

ICAM4 antisense RNA 1

  • Gene

    mitochondrial ribosomal protein L45


  • Gene

    long intergenic non-protein coding RNA 869


  • Gene

    zinc finger domain-containing protein LOC728743


  • Gene

    IGFL2 antisense RNA 1



  • Gene

    RNA component of signal recognition particle 7SL1


  • Gene

    napsin B aspartic peptidase (pseudogene)


  • Gene

    MPDU1 antisense RNA 1


  • Gene

    Fc gamma receptor Ib, pseudogene


  • Gene

    ICAM4 antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.